Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...

The Food and Drug Administration approved Jardiance (empagliflozin) as a once-daily oral tablet to treat type 2 diabetes in ...

Eli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on developing their big-selling Jardiance pill. Under the terms of the original ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), dapagliflozin produced a similar impact on MI/stroke risk but was associated with an increased risk of heart failure (HF) ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs increased from $3.5 to $27.5 billion ...

Revenues in the quarter benefited from a one-time payment of $300 million from partner Boehringer Ingelheim due to an amendment in their collaboration for Jardiance. Higher volumes of drugs like ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...